BioWin

From all of us at BioWin, we wish you a joyful holiday season filled with warmth, laughter, and sweet moments. 🎅 see you all in 2025! 

The Full-Life Technologies project is taking good shape in Gembloux, Belgium. This radioisotope manufacturing facility represents an €80 million investment and will ultimately create around 50 jobs. By 2026, under full capacity, it will provide Ac-225 therapies to tens of thousands of cancer patients each year 🤯 The construction of the facility started in December 2023 and obtained a Nuclear Permit for a class IIA facility from the Belgium Federal Agency for Nuclear Control in March 2024. Check out with Philippe van Put the amazing progress they have made so far!

It feels like the Christmas season has arrived a little early at Telix Manufacturing Solutions in Brussels South, where two new cyclotrons have been installed. These cyclotrons, supplied by GE HealthCare and IBA, strengthens Telix's position as a major nuclear medicine production facility, serving as the Company’s primary manufacturing site for radioisotopes and patient doses across the EMEA region and beyond. Darren Patti, Group Chief Operating Officer, Telix Pharmaceuticals Limited said, “This year, more than 10 million radiopharmaceutical procedures will be performed in the EU. These new cyclotrons, manufactured by the world leaders in particle accelerator technology, will deliver significant flexibility and reliable supply from Telix’s first bench-to-bedside manufacturing facility, to help meet this growing demand." 👉 Read the full release: https://lnkd.in/e9Wb-2mh

Member news! Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial. "We’ve reached a crucial point in the development of BIOX-101, which we believe can save lives, and improve quality of life," said Marc Dechamps, Chief Executive Officer at Bioxodes. 👉 Read the full release: https://lnkd.in/eVCg2GQs

✨ An early christmas gift for IRE - Institute for radioelements with the arrival of a 30 MeV IBA cyclotron at its Fleurus site. Total investment: over 30 million euros, including five million for the cyclotron alone. This “strategic investment” marks a “decisive step in IRE's drive to expand its production capacity and strengthen its leadership in radiopharmaceutical production. Erich Kollegger, CEO of IRE, stated: "The arrival of the IBA cyclotron is a significant turning point in IRE's history. This project demonstrates our capacity to innovate, diversify our activities, and control the entire production chain of essential radionuclides for nuclear medicine. We are committed to meeting the growing market needs and maintaining our position as an industry leader." 👉 See full article (French): https://lnkd.in/e5nt9K_r 👉 See full release: https://lnkd.in/e-Ka5sUr

Looking for funding to support your research on #RareDiseases? A new European funding opportunity has been launched to support collaborative research on rare diseases under the Horizon Europe program. This initiative is co-funded by the Service public de Wallonie as part of the ERDERA partnership. 👉 Learn more about the call: https://lnkd.in/dTQgBNuy

🇧🇪 Belgium's healthcare system is widely recognised for its comprehensive coverage, high accessibility, and good health outcomes. With a life expectancy of 82.5 years in 2023, it ranks among the top performers globally. However, the system is facing mounting challenges that could jeopardise its sustainability in the long-term. Growing demand for medical services, staff shortages, financial pressures, and concerns about sustainability are straining the availability and quality of care − a reality that Belgium cannot escape.   This whitepaper, commissioned by the Belgian Association Hospital Managers, provides a critical analysis of these challenges and evaluates the healthcare system’s readiness to adopt value-based healthcare (VBHC). Developed through extensive collaboration it integrates the views and opinions from stakeholders across Belgium’s healthcare ecosystem with one objective: proposing a unified vision and way forward for the future. Thank you to all BioWin members who contributed to the survey or the development of this whitepaper—your collaboration has been key to defining our shared path forward in Healthcare. 👉 Read it here: https://lnkd.in/gwm57XUs #healthcare PwC Belgium

PDC*line Pharma reports promising Phase I/II clinical results for its therapeutic lung cancer vaccine, recently presented at ESMO - European Society for Medical Oncology in Geneva. Its PDC*lung01 cancer vaccine, in combination with pembrolizumab, demonstrates the potential to provide meaningful clinical benefit compared to pembrolizumab alone in stage IV Non-Small Cell Lung Cancer patients with PD-L1 ≥ 50% and is associated with mild safety profile. 👉 Read the full news (FR): https://lnkd.in/e86fGxKc 👉 See the release: https://lnkd.in/etwb26jE

👋 Welcome the The OSICS Network to the BioWin Community! They empower pharma manufacturing companies with best-in-class tools, capabilities, and expertise to achieve operational excellence. "Joining BioWin aligns perfectly with our mission to drive operational excellence in the biotech and pharmaceutical sectors in Wallonia, helping the community stay competitive with other biotech clusters across Europe. Together, we strengthen talent development and contribute to the competitiveness of biopharma manufacturing facilities. Our senior industry specialists are here to provide their expertise and support the success of your product and process development." – Fabrice Le Garrec, Owner at The OSICS Network 👉 https://lnkd.in/gqGC9rT7

Are you a medtech professional interested in learning more about hospital financing in Belgium? Register now for beMedTech Masterclass on 18 December! Professor Katrien Kesteloot, an authority in hospital financing in our country, will provide insight into the various funding sources for hospitals in Belgium. She will discuss the latest developments in healthcare financing (e.g., fee-for-service models, recalibration of nomenclature, conventions, etc.) and give an overview of the current state of hospital financing reforms. Perhaps most importantly, she will also apply the theory to medical devices: what does all this mean for the financing of medical devices and investment goods in hospitals? 👉 More info: https://lnkd.in/egGJSrY5 #medtech #hospitals #financing